BPC 157 Dosing (Common Protocols), Oral Subcutaneous, 500 mcg daily, Duration: 6 weeks, Intramuscular Peritendinous, 1 mg daily, Duration: 6 weeks, Note:, Not approved by FDA or Frontiers Pharmacokinetics, distribution, metabolism, and excretion of body protective compound 157, a potential drug for treating various wounds, in rats and dogs BPC 157 Dosing (Common Protocols) Oral Subcutaneous 500 mcg daily Duration: 6 weeks Intramuscular Peritendinous 1 mg daily Duration: 6 weeks Note: Not approved BPC 157 Ulcerative Colitis LIVV Natural Frontiers Pharmacokinetics, distribution, metabolism, and excretion of body protective compound 157, a potential drug for treating various wounds, in rats and dogs